EQRx ideals all but abandoned amid reset
US drugmaker EQRx (Nasdaq: EQRX) had already signalled a shift away from its foundational principle to develop and deliver innovative medicines to patients at radically lower prices.
But the company has now shown the extent of the shift by talking of plans to reset its business, a move that will involve a new focus on high-value medicines.
"As part of this business reset, we plan to remove programs from our existing portfolio that are inconsistent with this new vision"There will be a prioritization of the development of lerociclib. A Phase III trial of the CDK 4/6 inhibitor in first-line advanced endometrial cancer has been started, while enrollment in a Phase II study in first- and second-line advanced breast cancer is nearing completion, providing what the company sees as a foundation for future combination development opportunities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze